The Japanese experience with thrombotic thrombocytopenic purpura-hemolytic uremic syndrome

被引:83
作者
Matsumoto, M
Yagi, H
Ishizashi, H
Wada, H
Fujimura, Y
机构
[1] Nara Med Univ, Dept Blood Transfus Med, Nara, Japan
[2] Nara Med Univ, Dept Internal Med 2, Nara, Japan
[3] Nara Med Univ, Dept Hlth Sci, Nara, Japan
[4] Mie Univ, Sch Med, Dept Clin Lab, Tsu, Mie 514, Japan
关键词
D O I
10.1053/j.seminhematol.2003.10.009
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
A total of 290 Japanese patients with thrombotic thrombocytopenic purpura-hemolytic uremic syndrome (TTP-HUS) were analyzed with respect to ADAMTS-13 activity and its inhibitor. Twenty-one patients (17 families) had Upshaw-Schulman syndrome, and 12 patients (six families) had familial HUS of undetermined etiology. The number of patients with acquired HUS and TTP was 44 and 213, respectively. In acquired TTP, patients with severe deficiency of ADAMTS-13 activity secondary to the presence of an inhibitor were high responders to plasma exchange, but others were low responders to plasma exchange. The former patients were associated with "idiopathic" TTP, drugs, and pregnancy, and the latter patients with malignancy and stem cell transplantation. Patients with autoimmune disease-associated TTP fit into both groups. © 2004 Elsevier Inc. All rights reserved.
引用
收藏
页码:68 / 74
页数:7
相关论文
共 35 条
[1]   Intensive plasma IgG removal therapy for severe thrombotic thrombocytopenic purpura [J].
Amano, SY ;
Inoue, M ;
Yoshida, Y ;
Yagi, H ;
Ishizashi, H ;
Matsumoto, M ;
Fujimura, Y ;
Yoshioka, A .
INTERNATIONAL JOURNAL OF HEMATOLOGY, 2002, 76 (05) :474-476
[2]   Successful treatment of a young infant who developed high-titer inhibitors against VWF-cleaving protease (ADAMTS-13): Important discrimination from Upshaw-Schulman syndrome [J].
Ashida, A ;
Nakamura, H ;
Yoden, A ;
Tamai, H ;
Ishizashi, H ;
Yagi, H ;
Matsumoto, M ;
Fujimura, Y .
AMERICAN JOURNAL OF HEMATOLOGY, 2002, 71 (04) :318-322
[3]  
Bell WR, 1997, SEMIN HEMATOL, V34, P134
[4]   Von Willebrand factor-cleaving protease and Upshaw-Schulman syndrome [J].
Fujimura, Y ;
Matsumoto, M ;
Yagi, H ;
Yoshioka, A ;
Matsui, T ;
Titani, K .
INTERNATIONAL JOURNAL OF HEMATOLOGY, 2002, 75 (01) :25-34
[5]   Deficient activity of von Willebrand factor-cleaving protease in chronic relapsing thrombotic thrombocytopenic purpura [J].
Furlan, M ;
Robles, R ;
Solenthaler, M ;
Wassmer, M ;
Sandoz, P ;
Lammle, B .
BLOOD, 1997, 89 (09) :3097-3103
[6]   Von Willebrand factor-cleaving protease in thrombotic thrombocytopenic purpura and the hemolytic-uremic syndrome [J].
Furlan, M ;
Robles, R ;
Galbusera, M ;
Remuzzi, G ;
Kyrle, PA ;
Brenner, B ;
Krause, M ;
Scharrer, I ;
Aumann, V ;
Mittler, U ;
Solenthaler, M ;
Lämmle, B .
NEW ENGLAND JOURNAL OF MEDICINE, 1998, 339 (22) :1578-1584
[7]   Aetiology and pathogenesis of thrombotic thrombocytopenic purpura and haemolytic uraemic syndrome:: the role of von Willebrand factor-cleaving protease [J].
Furlan, M ;
Lämmle, B .
BEST PRACTICE & RESEARCH CLINICAL HAEMATOLOGY, 2001, 14 (02) :437-454
[8]  
GASSER C, 1955, Schweiz Med Wochenschr, V85, P905
[9]  
KASPER CK, 1975, THROMB DIATH HAEMOST, V34, P869
[10]   Upshaw-Schulman syndrome revisited: A concept of congenital thrombotic thrombocytopenic purpura [J].
Kinoshita, S ;
Yoshioka, A ;
Park, YD ;
Ishizashi, H ;
Konno, M ;
Funato, M ;
Matsui, T ;
Titani, K ;
Yagi, H ;
Matsumoto, M ;
Fujimura, Y .
INTERNATIONAL JOURNAL OF HEMATOLOGY, 2001, 74 (01) :101-108